by Dimitar Ganev | Aug 15, 2018 | Blog
In their latest study on the pharma market, intelligence provider Evaluate pointed out that the development and commercialisation of gene and cell therapies are turning into a powerful engine of value creation for pharma companies. The launch of these novel therapies...
by Dimitar Ganev | Aug 7, 2018 | Blog
A recent research conducted by PwC and CB Insights found that venture capitalists invested $10.6 billion into healthcare start-ups in the first half of 2018, with $5.3 billion spent in 216 healthcare deals in the second quarter of the year – a 21% increase from the...
by Dimitar Ganev | Jul 27, 2018 | Blog
“Part of our competitors are not only the Novartis of the world and the other pharmas, but really the Amazons and Googles,” Yitzhak Peterburg, the former CEO of pharmaceutical giant Teva, said a year ago, adding that the global healthcare sector is facing a “huge...
by Dimitar Ganev | Jul 19, 2018 | Blog
As with the Brexit quandary, the economic turbulence surrounding the US-China trade skirmish presents an opportunity for many corporates to boost their brand presence in the media by establishing themselves as thought leaders. When reporting on the trade tensions...
by Dimitar Ganev | Jul 13, 2018 | Blog
As the two largest national economies embroil in a trade showdown, it is individual companies which are in the centre of extensive reportages and economic commentary: the dispute is not just between the two countries, but also between corporations and policy makers,...
